Primrose Bio Inc, a developer of proprietary therapeutic manufacturing technologies, announced on Wednesday that it has launched its Prima RNApols ExTend, an RNA polymerase engineered to improve manufacturing of long-template mRNA vaccines and therapeutics, including mRNA medicines based on self-amplifying mRNAs.

According to Primrose Bio, this enzyme shows improved performance, resulting in superior mRNA quality at a lower cost.

Prima RNApols ExTend is offered in an in vitro transcription kit for research use applications. It is produced and released under ISO 13485:2016 certified quality systems and offered for clinical and commercial mRNA manufacturing.

Helge Zieler, Primrose Bio CEO, said: "Prima ExTend is a much-needed innovation for the production of long-template mRNA therapeutics, that often struggle with integrity and quality issues that add risk to these programs. Our new enzyme is an important advancement for drug developers and researchers seeking high-integrity, high-yield mRNA."